CYTH - Cyclo Therapeutics to Present at the Virtual Investor Roundtable Event
Live moderated video webcast discussion with N. Scott Fine, Chief Executive Officer and Lise Lund Kjems, MD, PhD, Chief Medical Officer on Tuesday, November 16 th at 11:00 AM ET
Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that N. Scott Fine, Chief Executive Officer and Lise Lund Kjems, MD, PhD, Chief Medical Officer of Cyclo Therapeutics will participate in the Virtual Investor Roundtable Event on Tuesday, November 16, 2021 at 11:00 AM ET.
As part of the virtual event, the Company will provide a brief presentation, followed by a moderated roundtable discussion and an interactive Q&A session. In addition to the moderated portion of the event, all investors and interested parties will have the opportunity to submit questions live during the event. Interested parties may also pre-submit questions in advance of the live event, which can be sent via the conference website at virtualinvestorco.com. The Company will answer as many questions as possible during the event.
A live video webcast of the Roundtable Event will be available on the Events page of the Investors section of the Company’s website (cyclotherapeutics.com) . A webcast replay will be available two hours following the live presentation and will be accessible for one year.
About Cyclo Therapeutics:
Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from disease. The Company’s Trappsol ® Cyclo™, an orphan drug designated product in the United States and Europe, is the subject of four formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease, ( www.ClinicalTrials.gov NCT02939547 , NCT02912793 , NCT03893071 and NCT04860960 ). The Company is planning an early phase clinical trial using Trappsol ® Cyclo™ intravenously in Alzheimer’s Disease based on encouraging data from an Expanded Access program for late-onset Alzheimer’s Disease ( NCT03624842 ). Additional indications for the active ingredient in Trappsol ® Cyclo™ are in development. For additional information, visit the Company’s website: www.cyclotherapeutics.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211110005582/en/
JTC Team, LLC
Jenene Thomas
(833) 475-8247
CYTH@jtcir.com